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SUMMARY
The estimation of the HIV-AIDS epidemic by means of back-calculation (BC) has been difficult since the
introduction of highly active anti-retroviral therapy (HAART) because the incubation time distributions
needed for BC were poorly known. Moreover, it has been assumed that if the general public is aware
that effective treatments are available then the majority of infected people would be known, and therefore
a hidden epidemic was assumed not to exist. Nevertheless, it was suspected that not every infected
person would come to the attention of health-care providers, and therefore estimates independent of
the patients’ registration were necessary. In this paper, the incubation time distributions for HIV treated
with the HAART regimen are derived from a cohort study. By using estimates of the proportion treated
according to the HAART regimen and the incubation time distributions estimated in the era before the
implementation of HAART (pre-HAART), new marginal population incubation time distributions for each
of the three risk groups (homosexuals, drug users and others) were constructed. The BC was performed
using an empirical Bayesian approach based on the latter incubation time distribution. Copyright q 2007
John Wiley & Sons, Ltd.
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1. INTRODUCTION
The use of back-calculation (BC) for estimating the number of unobserved HIV cases has long
been an instrument of choice in the analysis of AIDS surveillance data. The crucial factor in the
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use of BC is an accurate description of the incubation time distribution either through a Markov
model or through a survival function derived from cohort studies [1–3]. The last update of HIV
incidence in Europe through BC occurred in 1996. Since the introduction of highly active anti-
retroviral therapy (HAART) in 1997, the shape and form of the incubation time distribution have
become uncertain, and prediction using BC only from AIDS-incidence data have been abandoned.
Aalen et al. [4] proposed a Markov model in which both the reported HIV incidence (i.e. the
treatment status of the patients) and AIDS incidence were taken into account, and therefore the
HIV incidence can be modeled without the need to use the incubation time distribution.
It has been argued that since the publication of HAART, people at risk of HIV–AIDS might
seek medical help at an earlier stage, such that virtually all HIV-infected people are registered.
An effort was made to set up databases containing all known HIV-positive patients. In [5–7],
an overview is given of the number of known HIV-diagnosed persons according to the year of
diagnosis. However, this does not provide the incidence of HIV cases by year of onset or the
number of unrecorded HIV infections.
Despite AIDS not being regarded as a threat in developed countries seven years after the
introduction of HAART, there is still some concern. HAART does not provide complete protection,
and because patients are required to adhere to a strict and complex drug regimen many become
non-adherent. There are also some signs that the HIV prevention campaigns are not as effective as
should be. Finally, the pharmaceutical industry simply wants to know how long and what quantity
of medication will be required in future. For these reasons, our aim is to estimate the total number
of HIV cases in the Netherlands by BC.
2. STUDY DESIGN
The cornerstone of the classic BC is the incubation time distribution, which reflects the incubation
period from HIV to AIDS. Previously, in 1996, the incubation time distribution for untreated
persons for the BC was derived from a Markov model, taking into account pre-AIDS death and
going back and forwards in the defined stages of CD4 counts [1, 2]. CD4 counts were given as six
categories, in decreasing numbers of CD4 cells per microliter. Group 1 being the group of patients
with the highest count, CD4900, group 2 with 900>CD4 700, group 3 700>CD4 500,
group 4 500>CD4 350, group 5 350 > CD4 200 and group 6 CD4< 200, respectively.
In the BC used for the European Union (EU) countries, the change of definition of AIDS and
the dependency of the incubation period on the age of onset were taken into account [3]. For
untreated persons, or persons not treated until the first HIV-positive test was performed, we still
believe this to be the best incubation time distributions available for the EU countries. As these
distributions were specifically adapted for each country using information on age distribution and
date of change for the definition of AIDS, in this study we will use the specific distribution derived
for the Netherlands. The incubation time distributions were all derived from disease progression
data for stages defined by CD4 counts using a Markov model [1, 2]. In Figure 1, pathways for
disease progression of an HIV-infected person are depicted. Note that HAART can occur only
after 1996, thus making the incubation distribution time dependent on the calendar time of the
first HIV test at which a decision for HAART was made.
For persons treated with anti-viral drugs based on their CD4 count, the estimation of the
incubation time distribution becomes more complex. We divided the drug regimens into two
different classes: HAART and pre-HAART. A regimen consisting of three or more different drugs
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Figure 1. Markov model of the disease progression from HIV to death. The numbers 1–6 refer to CD4
stage at first HIV test (see text). Pathways between CD4 stages are described in [1, 2], in which pre-AIDS
death is allowed, inclusion of age and change of AIDS definition in 1993 are described in [3].
Table I. Reported data adapted from [5–7].
Start End Homo Drugs Others Total At Risk (× 1000)
1978 1981 0 0 0 0 13 600
1981 1982 0 0 0 0 14 209
1982 1983 3 0 2 5 14 286
1983 1984 17 0 2 19 14 340
1984 1985 29 0 2 31 14 395
1985 1986 62 1 5 68 14 454
1986 1987 121 7 8 137 14 529
1987 1988 193 20 32 244 14 615
1988 1989 250 39 36 325 14 715
1989 1990 305 36 50 391 14 805
1990 1991 318 42 59 419 14 893
1991 1992 335 43 72 450 15 010
1992 1993 376 60 74 510 15 129
1993 1994 317 61 103 481 15 239
1994 1995 314 65 115 494 15 342
1995 1996 314 74 145 533 15 424
1996 1997 299 50 110 459 15 494
1997 1998 174 43 120 337 15 567
1998 1999 116 27 95 238 15 654
1999 2000 81 24 73 178 15 760
2000 2001 104 14 133 251 15 864
2001 2002 99 9 135 243 15 987
2002 2003 113 5 166 284 16 105
2003 2004 97 8 129 234 16 193
2004 2005 16 258
Note: At risk are the total population numbers of the Netherlands.
(e.g. two reverse transcriptase inhibitors and one protease inhibitor) was defined as HAART, while
regimens consisting of two or less different drugs, as was usual before the implementation of
HAART, were defined as pre-HAART. We used data from the HIV clinic at the University Medical
Centre of Groningen (UMCG) to estimate the incubation time distribution while on treatment. The
UMCG-HIV registration commenced in 1996 in anticipation that prospective and retrospective
HIV research would be required to be performed in future. This observational research database
comprises demographic data (e.g. age, gender and risk group), clinical data (e.g. HIV diagnosis,
results of blood tests and disease classification) and resource utilization data (e.g. inpatient days
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and medication use). This registry is maintained by employees at the UMCG-HIV clinic. All
persons in the registry with a first positive test were eligible for inclusion in this study. Patients
were excluded if their medication history was not complete for the period they were in the registry.
Patients were followed up till December 31, 2002, until they were removed from the registry or
until death. A total of 552 patients were eligible for inclusion in the study. The following was
recorded for each person: the CD4 count from the first positive test, the dates of starting and
stopping medication, the date of being diagnosed with AIDS and the date of death. Dates were
recorded in days and could be interval censored. Furthermore, we divided the patient population
into three different risk groups: (i) 152 homosexual men; (ii) 37 drug users; and (iii) 202 others.
The patients included in the risk group others mostly got infected by heterosexual transmission.
AIDS incidence data for the Dutch situation were used as published and updated in [5–7] and are
given in Table I.
3. INCUBATION TIME DISTRIBUTIONS
The incubation time distributions were estimated separately for the three risk groups and were
derived through survival functions. The reason to fit incubation distributions for each risk group
separately is that the course of the disease progression may depend on age, life style and other
aspects of the health status, which may differ considerably between risk groups. For example,
drug users have a greater risk for non-AIDS-related death, while the age distribution for the other
risk groups may be different. The different stages and the possible pathways from HIV infected
to AIDS or HIV infected to death, with the observed variations found in treatment regimes, are
depicted in Figure 1. The data were analyzed using a parametric survival regression allowing for
interval censoring (CensorReg from S-Plus, [8]). The best-fitted survival function appeared to be
an extreme-value function (Gumbel). The stage defined by the CD4 count at the first positive
HIV test was used as a categorical co-variate, while age and gender were ignored. For each risk
group, the contribution of CD4 counts as well as the scale parameter were kept constant across the
different pathways, while the intercept was allowed to vary. As we considered only the time from
a certain treated (or untreated) stage to AIDS, which can be reached by several pathways through
the different stages, we have to compute the convolution of the distributions associated with each
of the nodes in a possible pathway. See [3] for details.
3.1. The marginal incubation time distribution from onset to AIDS
It is necessary to construct the marginal incubation time distribution for persons from onset to
AIDS considering all possible pathways. For untreated persons and persons not treated until they
are found to be sero-positive (with a recorded CD4 level), we used the incubation time distribution
from the BC for the Dutch situation, which was published in 1996 [3].
In the classic BC model [9], the expected number of diagnosed AIDS cases yi in some time




P[xi |z j = 1] ·  j N j
where xi is the event of being diagnosed with AIDS, z j ∈ {0, 1} the event of being infected in time
interval j = 1, . . . , J and  j the relative incidence of unobserved persons being infected in the
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later time interval and N j the number at risk. We took for the number at risk the total population
in the Netherlands in the subsequent years, simply as a means to have a common denominator.
Usually one assumes for the distribution of yi a Poisson distribution conditional on the known
values of P[xi |z j ] and  j . Also, a log-normal distribution of  j is assumed with prior:
log[d(| 1 . . .  j−d)] ∝ N(0, −1)
for some fixed d , where d is the difference operator of order d . Usually, it is sufficient to take
first-order differences, i.e. d = 1, which we call the neighbor prior. The aim of BC is to estimate
 j , i.e. the (partly) hidden epidemic curve. See [9] for details of the estimation problem. What can
we say of P[xi |z j ] in the light of treatment effects? If no treatment would have been applied, we
could safely use the discrete version of incubation time distribution used in earlier publications.
However, since at some time j = t0 pre-HAART and HAART treatments have been used, this must
be taken into account. We may write in general the convolution:





P[CD4t−i = k|z j = 1]P[xi |z j = 1 ∧ CD4t−i = k]
where CD4t−i = k is the event of an untreated person being in the kth class of the CD4 classes
(k = 1, . . . , 6) at time period t − i . The moment a person gets treated we have to change the
probability of getting AIDS in the last term of the summation.
Now, from j = t0 on, there is a chance that an infected person will get on treatment with pre-
HAART or HAART. Assume that there exist non-zero probabilities skl s = t0, . . . , J that a person
starts treatment l when arriving at a certain class k of CD4 counts at time s. We may then derive
the following equality:
P[xi |z j = 1 ∧ CD4t−i = k] =∑
l
t−ikl P[xi |z j = 1 ∧ CD4t−i = k ∧ Itreatment=l ]
The treatment indicator is in the case of three treatments, untreated (0), pre-HAART (1) and
HAART (2), while in the case of two treatments we drop the category pre-HAART.
However, as we already have the ‘old’ incubation time distribution for untreated persons, this
equation is not used for untreated persons. Thus, given the probabilities skl , s = t0, . . . , J , we
have to derive the probability of getting AIDS in time period i when infected at a certain time j
using the ‘old’ incubation time distributions, together with the prevalence of being in class k of
the CD4 counts derived from these, and the new extreme value distributions for each pathway










P[CD4t−i = k|z j = 1]
2∑
l=0
t−ikl P[xi |z j = 1 ∧ CD4t−i = k ∧ Itreatment=l ]
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We write the above equation in a form that enables us to discriminate between the untreated
and treated persons















P[CD4t−i = k|z j = 1]
2∑
l=1
t−ikl P[xi |z j = 1 ∧ CD4t−i = k ∧ Itreatment=l ]
It is clear that only for i<t0 the incubation incidence is simply the untreated one. For it0
it is not possible to use the untreated incubation distribution directly as for the untreated per-
sons we have to down-weight the tail of the distribution by the probability of going onto
treatment.
As the incubation time distribution for the untreated persons is not available in the fine de-
tails needed, we used the following approximation to the untreated part of the incubation time
distribution:
P[xi |z j = 1 ∧ Itreatment=0] = wi, j P0[xi |z j = 1]wi, j
⎧⎪⎪⎨
⎪⎪⎩
1, i<t0 ∧ j<t0
¯0, it0 ∧ jt0
¯0e
( j−i), it0 ∧ j<t0
where P0[·] is the original distribution function, ¯0 the average proportion not on treatment and 
some tuning constant. Thus, we down-weight the original distribution heavier for those who are
infected before the treatment regimes started. Constraints are applied on the weights such that the
weights and the mean probabilities of getting treatment sum to 1.
It may be tempting to try to estimate the probabilities tkl simultaneously with  j as we have
a finite mixture of distributions. However, when fitted with a fixed arbitrary tkl , it is clear that
a fit with ¯ j = tkl j will fit equally well and thus cancel out the other treated components, or
vice versa. Unless there is explicit information on the AIDS-diagnosed patients with respect to
their treatment status, a simultaneous fit is impossible. Thus, we estimated the proportions on
treatment from the Groningen cohort by a simple generalized linear model for each risk group.
From this we concluded that—after 1999—the proportion on treatment remained constant and
apart from the risk-group ‘others’, were independent of CD4 class. We chose to ignore the latter
dependance as the numbers on which these estimates were based were small. The estimated
treatment proportions increased from 0.11 in 1996 to 0.45 in 1999 and we used the indices of
the treatment proportion depending linearly on time from 1996 onwards until 2000. In Figure
2, the marginal distributions are given on the basis of the selected infection cohorts for homo-
sexual men.
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Risk group homosexual men untreated and HAART 
Figure 2. Incubation time distributions for selected infection cohorts of homosexual men.
4. FITTED BACK-CALCULATION MODELS
For each separate risk group, a BC model was fitted to estimate the relative incidence of HIV,
using the number of inhabitants as the number of people at risk, i.e. a log-link with the log
of the number at risk as offset. We tried marginal incubation time distributions based on two-
and three-treatment classes, and subsequently used the Akaike Information Criterion (AIC) as the
goodness-of-fit measure. For all of the risk groups—except drug users—the two-treatment marginal
incubation time distribution gave by far the smallest AIC. Only the risk group of drug users fitted
much better with three-treatment classes. Figures 2–8 depict for each risk group (i) the fitted AIDS
incidence in numbers and (ii) the relative HIV incidence (per 1000), all with the accompanying
predictions from 2005 to 2010. The figures were created using incubation time distribution based
on two-treatment classes for all risk groups. The 95 per cent prediction limits are based on the use
of the negative binomial distribution, details of which can be found in [9]. Note that the predictions
for the relative HIV incidence after 2003 are simply the last carry forward of the estimate in 2003
as a result of the neighbor prior in the Bayesian prediction model.
4.1. Prevalence and cumulative incidence of HIV in the Netherlands
We estimated for each year (i) the AIDS incidence with their prediction intervals, (ii) the HIV
incidence and prevalence with their prediction intervals, (iii) death incidence and (iv) the cumulative
numbers of HIV cases and deceased for each risk group. For reasons of brevity, we include in
Table II only HIV prevalence and cumulative incidence for the three risk groups. In particular,
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Risk group homosexual men untreated and HAART
Figure 4. Relative HIV incidence per 1000 for homosexual men.
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Risk group drugs users untreated and HAART 

























 Risk group drugs users untreated and HAART 
Figure 6. Relative HIV incidence per 1000 for drugs users.
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Risk group others untreated and HAART























Risk group others untreated and HAART 
Figure 8. Relative HIV incidence per 1000 and prediction for risk group ‘others’.
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Table II. Estimated HIV-cumulative incidence and HIV incidence in absolute numbers for
homosexual men, drugs users and risk group others.
Homosexual men Drugs users Others
Year HIV cumulative Prevalence HIV cumulative Prevalence HIV cumulative Prevalence
1981 216 197 1 1 59 55
1982 286 262 1 1 81 75
1983 472 436 3 2 106 98
1984 1178 1115 7 5 15 139
1985 2542 2427 19 13 236 216
1986 3396 3191 45 32 372 340
1987 3830 3487 97 72 553 502
1988 4082 3553 197 147 748 672
1989 4253 3492 386 303 931 820
1990 4385 3355 683 563 1089 931
1991 4498 3172 806 644 1223 1007
1992 4600 2964 868 661 1342 1056
1993 4698 2746 917 660 1456 1091
1994 4794 2530 962 653 1578 1124
1995 4889 2324 995 631 1730 1178
1996 4982 2131 1014 595 1956 1298
1997 5072 1952 1024 550 2360 1588
1998 5158 1920 1031 503 3186 2280
1999 5239 1892 1035 495 5121 4153
2000 5317 1870 1038 486 6004 4957
2001 5391 1851 1041 479 6536 5389
2002 5460 1835 1045 472 6952 5685
2003 5524 1803 1048 464 7324 5920
2004 5583 1774 1052 458 7680 6118
2005 5637 1747 1057 452 8029 6293
2006 5685 1724 1062 448 8373 6453
2007 5729 1708 1069 445 8715 6604
2008 5767 1695 1076 444 9057 6753
2009 5800 1681 1085 445 9399 6905
2010 5827 1665 1095 448 9747 7064
the cumulative number of HIV cases is interesting. At the beginning of the epidemic in 1987, the
cumulative cases of HIV-infected persons was estimated to be 12 000. This estimate was lowered to
9 000 in 1995 [3]. The cumulative number of recorded HIV persons as of June 2005 is, according
to [7], 5556 for homosexual men, 563 for drug users and 4500 for the risk group others. From
Table II, our estimates for the cumulative incidence by the end of 2004 are 5583 for the risk group
of homosexual men, 1052 for drug users and 7680 for the risk group others. Allowing for a linear
interpolation between the estimates for the end of 2004 and 2005, our estimates until June 2005
are: 5605, 1053 and 7825, respectively. Thus, there is a very good agreement in our estimates for
the risk group homosexual men and that of the UMCG database. This implies that homosexual men
are more aware of their risk for HIV/AIDS. The discrepancy for the drug users is most likely due
to our modeling technique. Specifically, our pre-HAART model assumed that there was an extra 15
per cent of deaths before AIDS (and probably HIV) was diagnosed [3]. In addition, pre-HAART
drug users accounted for the majority of the pre-HAART incidence in the total population. If our
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incubation time distribution is correct, there are approximately 3300 HIV-infected persons missing
from the risk group others, which is likely due to mostly heterosexual transmission. It is clear that
for the risk groups homosexual men and intravenous drug users the epidemic is over. The risk
group others (which comprises mostly of heterosexuals) had a maximum incidence in 1995, which
coincides with the EU report in 1996. After the peak in 1995, the incidence has decreased, but is
still at a higher level than prior to 1993 and at a much higher level than in the homosexual men
and drug user groups. It is of concern to the public health authorities in the Netherlands that 43
per cent of the risk group others is not registered in the database and therefore they are probably
unaware of their HIV status. We estimate that by the end of 2004 the prevalence among the risk
group others is 6118 (95 per cent prediction interval: 5475–6835). While the prevalence among
the risk group of homosexual men is 1774 (1668–1886), intravenous drug users account for 485
(288–729) persons. Thus, we estimate that from the total HIV-infected population, 73 per cent
belongs to the risk group others, in contrast to the reported estimate of 43 per cent in [7].
5. DISCUSSION AND CONCLUSION
We have derived a method of estimating the total incidence of HIV from publicly available AIDS-
incidence data, without the need for detailed information about each individual’s treatment history.
The incubation time distributions, which are needed for classic BC, were derived by means of both
the known distributions for untreated persons used in [3] (available from the first author for other
EU countries as S-Plus files), and fitted distributions from a local cohort, together with information
on the proportion of persons going on different treatment regimes. Although the possibility exists
that the incubation time distributions derived for treated persons have a local component because
treatments are adapted to the local population locally, these incubation time distributions could be
used by other countries in the absence of other information. Thus, the only truly local parameters
are the proportions of persons commencing treatment as defined above, which can be simply
estimated from hospital-based data. We therefore believe that the derived methodology can be
applied to other EU countries as well. From the first author’s incubation time distributions for
the EU countries as used in [3], the parameters used in the extreme value distributions as well
as S-Plus software for BC are available. The results of our study suggest that for the classic risk
groups (homosexual men and intravenous drug users) there is evidence that the recorded HIV
infections are well covered. This is probably due to the thorough follow-up of patients by the
health-care professionals, awareness created by the health authorities and the Dutch government’s
policy regarding the use of hard drugs. However, it is apparent that heterosexuals who form the
majority of the others risk group are receiving little attention. In fact, we estimate that 43 per cent
of the others group is not registered and, therefore, they are probably unaware of their infection
status. Moreover, we estimate that the others account for a much higher (73 per cent) percentage
of the total infected population than the recently reported 43 per cent in [7].
5.1. Convolution of extreme value distributions
In this section, the distribution of the sum of independently distributed extreme value distributions
with common-scale parameter is derived. Let Xi , i = 1, . . . , k, be independent stochastic variables
with the extreme value distribution with location parameters , i = 1, . . . , k, and the common-scale
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parameter :
FXi (x, i , )= e−e
−(x−i )/ − ∞<i<∞, >0, i = 1, . . . , k (1)
The mean and variance of this distribution are i + 0.577216 and 22/6, respectively, see [10].
We seek the cumulative distribution of Z =∑i Xi . The moment-generating function of (1) is
given by
MXi (t) = ei t (1 −  t) (2)
From standard theory, it follows that the moment-generating function of
∑
i Xi equals:
MZ (t) = e
∑
i i t ((1 − t))k with Z =∑
i
Xi
= (et ¯(1 − t))k with ¯=∑
i
i (3)
From this, it follows that the distribution of Z is given by the convolution of k independent
identically distributed Gumbel distributions given by (1) with parameters ¯ and . It is in principle
possible to find the density function by a complex integration from (3), but the form looks
intractable for convolutions k>2. Numerical comparison reveals that for k not too large the form
of the distribution will remain Gumbel. Thus, by letting the first two moments of Z , assuming
a Gumbel distribution, coincide with the first two moments of the sum of identically distributed
Gumbel distributions with parameters ¯ and , we find that the parameters of the corresponding
Gumbel distribution of Z are approximately:
˜=∑
i




However, for k = 2, we may derive directly from the convolution of two i.i.d. Gumbel distribu-
tions the corresponding distribution. Thus, let Z = X +Y, with Z and Y independently distributed.




FY (z − x) fX (x) dx
where FY and fx denote the c.d.f. of Y and the p.d.f. of Y , respectively. The p.d.f. of the Gumbel
distribution is
fX (x, , )= 1

e−e−(x−)/e−(x−)/
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= (1 + e−(z−2)/)−1
By a change of variables, i.e. w= e−(z−2)/, and thus translating the time z into z = 2− log(w),
we see that w has exactly the standard logistic distribution with mean 0 and variance 2/3.
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